Actualités UCB (PK) - UCBJY | Actions OTCMarkets

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Schedule 13g
(sc 13g/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of...

Schedule 13g
(sc 13g/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of...

Post-effective Amendment to a Previously Filed F-6. (f-6 Pos)

333-156660 SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services

UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services Judges highlight value-added partnership and finance...

New Data Identify Important Factors that May Reduce Hospitalizations among People with Epilepsy in the U.S.

New Data Identify Important Factors that May Reduce Hospitalizations among People with Epilepsy in the U.S. Results of retrospective analysis...

UCB Announces Crohn's Disease Data to be Presented at Digestive Disease Week 2015

UCB Announces Crohn's Disease Data to be Presented at Digestive Disease Week 2015 PR Newswire ATLANTA, May 16, 2015 ATLANTA, May 16, 2015...

Small Company Offering and Sale of Securities Without Registration (d)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. FORM...

UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam

UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam - Major milestone for brivaracetam is latest...

UCB and Emory Present New Assessment of Epilepsy Prevalence and Incidence in the U.S. at 2014 American Epilepsy Society Annua...

UCB and Emory Present New Assessment of Epilepsy Prevalence and Incidence in the U.S. at 2014 American Epilepsy Society Annual Meeting PR...

UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of...

UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

UCB (PK) (UCBJY)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

UCBJY Actualités

Schedule 13g
(sc 13g/a)

Schedule 13g
(sc 13g/a)

Post-effective Amendment to a Previously Filed F-6. (f-6 Pos)

UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services

New Data Identify Important Factors that May Reduce Hospitalizations among People with Epilepsy in the U.S.

UCB Announces Crohn's Disease Data to be Presented at Digestive Disease Week 2015

Small Company Offering and Sale of Securities Without Registration (d)

UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam

UCB and Emory Present New Assessment of Epilepsy Prevalence and Incidence in the U.S. at 2014 American Epilepsy Society Annua...

UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of...

UCB, Georgia Institute of Technology Partner to Harness the Power of Predictive Analytics in Epilepsy Care

UCB reinforces its leadership in epilepsy at the 2014 Annual Meeting of the American Epilepsy Society (AES)

UCB shows strong scientific presence at leading rheumatology meeting

Advent International and Avista Capital Partners to Acquire Kremers Urban Pharmaceuticals from UCB

Securities Registration (ads, Immediate) (f-6ef)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

UCB (PK) (UCBJY) Actualités

UCB (PK) (UCBJY)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

UCBJY Actualités

Schedule 13g (sc 13g/a)

Schedule 13g (sc 13g/a)

Post-effective Amendment to a Previously Filed F-6. (f-6 Pos)

UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services

New Data Identify Important Factors that May Reduce Hospitalizations among People with Epilepsy in the U.S.

UCB Announces Crohn's Disease Data to be Presented at Digestive Disease Week 2015

Small Company Offering and Sale of Securities Without Registration (d)

UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam

UCB and Emory Present New Assessment of Epilepsy Prevalence and Incidence in the U.S. at 2014 American Epilepsy Society Annua...

UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of...

UCB, Georgia Institute of Technology Partner to Harness the Power of Predictive Analytics in Epilepsy Care

UCB reinforces its leadership in epilepsy at the 2014 Annual Meeting of the American Epilepsy Society (AES)

UCB shows strong scientific presence at leading rheumatology meeting

Advent International and Avista Capital Partners to Acquire Kremers Urban Pharmaceuticals from UCB

Securities Registration (ads, Immediate) (f-6ef)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Schedule 13g
(sc 13g/a)

Schedule 13g
(sc 13g/a)